Table 3 Median time in months (range) between submission to Health Canada and pCPA Agreement
Step in pathway | All drugs with health Canada approval (n = 41) | Drugs for cancer indications (n = 15) | Drugs for Non-cancer indications (n = 26) | Drugs for indications with an incidence of 1–5/10,000 | Drugs for indications with an incidence of < 1/10,000 |
|---|---|---|---|---|---|
Health Canada Submission to Health Canada Approval (months, range) | 6.9 (6.0–23.7) | 8.3 (6.1–18.5) | 6.8 (6.0–23.7) | 6.5 (6.0–18.5) | 8.4 (6.1–23.7) |
Health Canada Approval to HTA (CADTH) Recommendation (months, range) | 6.0 (1.1–20.0) | 5.0 (3.1–18.0) | 7.6 (1.5–20.1) | 5.5 (1.5–15.2) | 6.1 (1.1–20.1) |
HTA (CADTH) Recommendation to pCPA Agreement (months, range) | 9.8 (1.6–24.8) | 9.9 (4.3–14.6) | 9.6 (1.6–24.8) | 10.2 (4.3–18.2) | 8.0 (1.6–24.8) |